Comparative two-dimensional polyacrylamide gel electrophoresis of the salivary proteome of children with autism spectrum disorder

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 11, 2015, Pages 2664-2678

  Ngounou Wetie, Armand G ^a   Wormwood, Kelly L ^a   Charette, Laci ^b   Ryan, Jeanne P ^b   Woods, Alisa G ^a,b   Darie, Costel C ^a  

^a CLARKSON UNIVERSITY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

2D PAGE; Autism spectrum disorder; Early diagnosis; NanoLC MS MS

Indexed keywords

ALPHA2 GLYCOPROTEIN; ALPHA6 INTEGRIN; AMYLASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYSTATIN; KINESIN; MUCIN; PLASMINOGEN; PROLACTIN; PROTEOME; TRANSFERRIN; ZYMOGEN GRANULE; SALIVA PROTEIN;

ADOLESCENT; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SALIVA ANALYSIS; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; UPREGULATION; AUTISM SPECTRUM DISORDER; COMPARATIVE STUDY; METABOLISM; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AUTISM SPECTRUM DISORDER; CHILD; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; PROTEOME; SALIVARY PROTEINS AND PEPTIDES; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84945443308     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12658     Document Type: Article

References (99)

1. Tordjman S, Somogyi E, Coulon N, et al. Gene x environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Front Psychiatry. 2014; 5: 53.
2. Volkmar FR, McPartland JC. From Kanner to DSM-5: autism as an evolving diagnostic concept. Annual review of clinical psychology. 2014; 10: 193-212.
3. Jon Baio. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014; 63: 1-21.
4. Hansen SN, Schendel DE, Parner ET. Explaining the increase in the prevalence of autism spectrum disorders: the proportion attributable to changes in reporting practices. JAMA Pediatr. 2015; 169: 56-62.
5. Woods AG, Mahdavi E, Ryan JP. Treating clients with Asperger's syndrome and autism. Child and adolescent psychiatry and mental health. 2013; 7: 32.
6. Bishop DV, Whitehouse AJ, Watt HJ, et al. Autism and diagnostic substitution: evidence from a study of adults with a history of developmental language disorder. Dev Med Child Neurol. 2008; 50: 341-5.
7. Shelton JF, Geraghty EM, Tancredi DJ, et al. Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: the CHARGE study. Environ Health Perspect. 2014; 122: 1103-9.
8. Brown AS, Surcel HM, Hinkka-Yli-Salomaki S, et al. Maternal thyroid autoantibody and elevated risk of autism in a national birth cohort. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 57C: 86-92.
9. Flatscher-Bader T, Foldi CJ, Chong S, et al. Increased de novo copy number variants in the offspring of older males. Transl Psychiatry. 2011; 1: e34.
10. Maramara LA, He W, Ming X. Pre- and perinatal risk factors for autism spectrum disorder in a new jersey cohort. J Child Neurol. 2014; 29: 1645-51.
11. Tuchman R, Alessandri M, Cuccaro M. Autism spectrum disorders and epilepsy: moving towards a comprehensive approach to treatment. Brain Dev. 2010; 32: 719-30.
12. Mayer EA, Padua D, Tillisch K. Altered brain-gut axis in autism: comorbidity or causative mechanisms? BioEssays. 2014; 36: 933-9.
13. McPhillips M, Finlay J, Bejerot S, et al. Motor deficits in children with autism spectrum disorder: a cross-syndrome study. Autism Res. 2014; 7: 664-76.
14. Curtin C, Bandini LG, Perrin EC, et al. Prevalence of overweight in children and adolescents with attention deficit hyperactivity disorder and autism spectrum disorders: a chart review. BMC Pediatr. 2005; 5: 48.
15. Gesundheit B, Rosenzweig JP, Naor D, et al. Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun. 2013; 44: 1-7.
16. Saxena V, Ramdas S, Ochoa CR, et al. Structural, genetic, and functional signatures of disordered neuro-immunological development in autism spectrum disorder. PLoS ONE. 2012; 7: e48835.
17. Bilder D, Botts EL, Smith KR, et al. Excess mortality and causes of death in autism spectrum disorders: a follow up of the 1980s Utah/UCLA autism epidemiologic study. J Autism Dev Disord. 2013; 43: 1196-204.
18. Staal WG. Autism, DRD3 and repetitive and stereotyped behavior, an overview of the current knowledge. Eur Neuropsychopharmacol. 2015; 25: 1421-6.
19. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007; 9: 343-54.
20. Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014; 45: 185-92.
21. Cunningham AB. Measuring change in social interaction skills of young children with autism. J Autism Dev Disord. 2012; 42: 593-605.
22. Wallace KS, Rogers SJ. Intervening in infancy: implications for autism spectrum disorders. J Child Psychology Psychiatry. 2010; 51: 1300-20.
23. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012; 17: 389-401.
24. Frye RE, James SJ. Metabolic pathology of autism in relation to redox metabolism. Biomark Med. 2014; 8: 321-30.
25. Tierney E, Bukelis I, Thompson RE, et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet Neuropsychiatr Genet. 2006; 141B: 666-8.
26. Walsh P, Elsabbagh M, Bolton P, et al. In search of biomarkers for autism: scientific, social and ethical challenges. Nat Rev Neurosci. 2011; 12: 603-12.
27. Ebert MP, Meuer J, Wiemer JC, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res. 2004; 3: 1261-6.
28. Chen J, Kahne T, Rocken C, et al. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res. 2004; 3: 1009-16.
29. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008; 452: 571-9.
30. Hortin GL, Jortani SA, Ritchie JC Jr, et al. Proteomics: a new diagnostic frontier. Clin Chem. 2006; 52: 1218-22.
31. Zhang H, Liu AY, Loriaux P, et al. Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics. 2007; 6: 64-71.
32. Wetie AG, Dekroon RM, Mocanu M, et al. Mass spectrometry for the study of autism and neurodevelopmental disorders. Adv Exp Med Biol. 2014; 806: 525-44.
33. Ngounou Wetie AG, Wormwood K, Thome J, et al. A pilot proteomic study of protein markers in autism spectrum disorder. Electrophoresis. 2014; 35: 2046-54.
34. Ngounou Wetie AG, Wormwood K, Russell S, et al. A pilot proteomic analysis of salivary biomarkers in autism spectrum disorder. Autism Res. 2015; 8: 338-50.
35. Sokolowska I, Woods AG, Gawinowicz MA, et al. Identification of a potential tumor differentiation factor receptor candidate in prostate cancer cells. FEBS J. 2012; 279: 2579-94.
36. Wetie AG, Shipp DA, Darie CC. Bottlenecks in proteomics. Adv Exp Med Biol. 2014; 806: 581-93.
37. Woods AG, Wormwood KL, Wetie AG, et al. Autism spectrum disorder: an omics perspective. Proteomics Clin Appl. 2015; 9: 159-68.
38. Chen Y, Azman SN, Kerishnan JP, et al. Identification of host-immune response protein candidates in the sera of human oral squamous cell carcinoma patients. PLoS ONE. 2014; 9: e109012.
39. Costa O, Schneider P, Coquet L, et al. Proteomic profile of pre - B2 lymphoblasts from children with acute lymphoblastic leukemia (ALL) in relation with the translocation (12; 21). Clin Proteomics. 2014; 11: 31.
40. Giusti L, Baldini C, Bazzichi L, et al. Proteome analysis of whole saliva: a new tool for rheumatic diseases-the example of Sjogren's syndrome. Proteomics. 2007; 7: 1634-43.
41. Chiocchetti AG, Haslinger D, Boesch M, et al. Protein signatures of oxidative stress response in a patient specific cell line model for autism. Mol Autism. 2014; 5: 10.
42. Braunschweig D, Krakowiak P, Duncanson P, et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl Psychiatry. 2013; 3: e277.
43. Deng MY, Lam S, Meyer U, et al. Frontal-subcortical protein expression following prenatal exposure to maternal inflammation. PLoS ONE. 2011; 6: e16638.
44. Junaid MA, Kowal D, Barua M, et al. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A. 2004; 131: 11-7.
45. Williams KM, Marshall T. Urinary protein patterns in autism as revealed by high resolution two-dimensional electrophoresis. Biochem Soc Trans. 1992; 20: 189S.
46. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003; 4: P3.
47. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 2013; 41: D377-86.
48. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011; 39: D561-8.
49. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975; 250: 4007-21.
50. Burgess-Cassler A, Johansen JJ, Santek DA, et al. Computerized quantitative analysis of coomassie-blue-stained serum proteins separated by two-dimensional electrophoresis. Clin Chem. 1989; 35: 2297-304.
51. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985; 150: 76-85.
52. Oakley BR, Kirsch DR, Morris NR. A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels. Anal Biochem. 1980; 105: 361-3.
53. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols. 2009; 4: 44-57.
54. Chen CL, Lin TS, Tsai CH, et al. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. J Proteomics. 2013; 85: 28-43.
55. Mu Y, Chen Y, Zhang G, et al. Identification of stromal differentially expressed proteins in the colon carcinoma by quantitative proteomics. Electrophoresis. 2013; 34: 1679-92.
56. Jou YJ, Lin CD, Lai CH, et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010; 681: 41-8.
57. Talkowski ME, Minikel EV, Gusella JF. Autism spectrum disorder genetics: diverse genes with diverse clinical outcomes. Harv Rev Psychiatry. 2014; 22: 65-75.
58. Zakowski JJ, Bruns DE. Biochemistry of human alpha amylase isoenzymes. Crit Rev Clin Lab Sci. 1985; 21: 283-322.
59. Nater UM, Rohleder N, Schlotz W, et al. Determinants of the diurnal course of salivary alpha-amylase. Psychoneuroendocrinology. 2007; 32: 392-401.
60. Cheshire WP. Highlights in clinical autonomic neuroscience: new insights into autonomic dysfunction in autism. Auton Neurosci. 2012; 171: 4-7.
61. Anderson CJ, Colombo J, Unruh KE. Pupil and salivary indicators of autonomic dysfunction in autism spectrum disorder. Dev Psychobiol. 2013; 55: 465-82.
62. Crider A, Thakkar R, Ahmed AO, et al. Dysregulation of estrogen receptor beta (ERbeta), aromatase (CYP19A1), and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects. Mol Autism. 2014; 5: 46.
63. Roelfsema JH, Peters DJ. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med. 2007; 9: 1-16.
64. Schorry EK, Keddache M, Lanphear N, et al. Genotype-phenotype correlations in Rubinstein-Taybi syndrome. Am J Med Genet A. 2008; 146A: 2512-9.
65. Marangi G, Leuzzi V, Orteschi D, et al. Duplication of the Rubinstein-Taybi region on 16p13.3 is associated with a distinctive phenotype. Am J Med Genet A. 2008; 146A: 2313-7.
66. Thienpont B, Bena F, Breckpot J, et al. Duplications of the critical Rubinstein-Taybi deletion region on chromosome 16p13.3 cause a novel recognisable syndrome. J Med Genet. 2010; 47: 155-61.
67. Rosa JL, Barbacid M. A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70. Oncogene. 1997; 15: 1-6.
68. Webb DW, Fryer AE, Osborne JP. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol. 1996; 38: 146-55.
69. Gillberg IC, Gillberg C, Ahlsen G. Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. Dev Med Child Neurol. 1994; 36: 50-6.
70. Hunt A, Shepherd C. A prevalence study of autism in tuberous sclerosis. J Autism Dev Disord. 1993; 23: 323-39.
71. Pan D, Dong J, Zhang Y, et al. Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol. 2004; 14: 78-85.
72. Chong-Kopera H, Inoki K, Li Y, et al. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem. 2006; 281: 8313-6.
73. Puffenberger EG, Jinks RN, Wang H, et al. A homozygous missense mutation in HERC2 associated with global developmental delay and autism spectrum disorder. Hum Mutat. 2012; 33: 1639-46.
74. Loeffler DA, Connor JR, Juneau PL, et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem. 1995; 65: 710-24.
75. Chauhan A, Chauhan V, Brown WT, et al. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins. Life Sci. 2004; 75: 2539-49.
76. Wang H. Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders. Front Behav Neurosci. 2014; 8: 104.
77. Ngounou Wetie AG, Wormwood K, Thome J, et al. A pilot proteomic study of protein markers in autism spectrum disorder. Electrophoresis. 2014; 35: 2046-54.
78. Lauritsen MB, Als TD, Dahl HA, et al. A genome-wide search for alleles and haplotypes associated with autism and related pervasive developmental disorders on the Faroe Islands. Mol Psychiatry. 2006; 11: 37-46.
79. Alvarez-Fernandez M, Liang YH, Abrahamson M, et al. Crystal structure of human cystatin D, a cysteine peptidase inhibitor with restricted inhibition profile. J Biol Chem. 2005; 280: 18221-8.
80. Nishimura Y, Martin CL, Vazquez-Lopez A, et al. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet. 2007; 16: 1682-98.
81. Campbell DB, Li C, Sutcliffe JS, et al. Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res. 2008; 1: 159-68.
82. Hino S, Michiue T, Asashima M, et al. Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin. J Biol Chem. 2003; 278: 14066-73.
83. Kalkman HO. A review of the evidence for the canonical Wnt pathway in autism spectrum disorders. Mol Autism. 2012; 3: 10.
84. Blaker-Lee A, Gupta S, McCammon JM, et al. Zebrafish homologs of genes within 16p11.2, a genomic region associated with brain disorders, are active during brain development, and include two deletion dosage sensor genes. Dis Model Mech. 2012; 5: 834-51.
85. Devillard F, Guinchat V, Moreno-De-Luca D, et al. Paracentric inversion of chromosome 2 associated with cryptic duplication of 2q14 and deletion of 2q37 in a patient with autism. Am J Med Genet A. 2010; 152A: 2346-54.
86. O'Roak BJ, Vives L, Girirajan S, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012; 485: 246-50.
87. Cochrane LE, Tansey KE, Gill M, et al. Lack of association between markers in the ITGA3, ITGAV, ITGA6 and ITGB3 and autism in an Irish sample. Autism Res. 2010; 3: 342-4.
88. Mercier F, Cho Kwon Y, Kodama R. Meningeal/vascular alterations and loss of extracellular matrix in the neurogenic zone of adult BTBR T+ tf/J mice, animal model for autism. Neurosci Lett. 2011; 498: 173-8.
89. Lu C, Kasik J, Stephan DA, et al. Grtp1, a novel gene regulated by growth hormone. Endocrinology. 2001; 142: 4568-71.
90. Pinto D, Pagnamenta AT, Klei L, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010; 466: 368-72.
91. Geetha C, Venkatesh SG, Dunn BH, et al. Expression and anti-bacterial activity of human parotid secretory protein (PSP). Biochem Soc Trans. 2003; 31: 815-8.
92. Geetha C, Venkatesh SG, Bingle L, et al. Design and validation of anti-inflammatory peptides from human parotid secretory protein. J Dent Res. 2005; 84: 149-53.
93. Hassan MI, Waheed A, Yadav S, et al. Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications. Cell Mol Life Sci. 2009; 66: 447-59.
94. D'Eufemia P, Celli M, Finocchiaro R, et al. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996; 85: 1076-9.
95. Ryckman C, Vandal K, Rouleau P, et al. Proinflammatory activities of S100: proteins S10OA8, S10OA9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol. 2003; 170: 3233-42.
96. Ghavami S, Eshragi M, Ande SR, et al. S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res. 2010; 20: 314-31.
97. Li C, Chen H, Ding F, et al. A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway. Biochem J. 2009; 422: 363-72.
98. von Mering C, Jensen LJ, Snel B, et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005; 33: D433-7.
99. Roke Y, Buitelaar JK, Boot AM, et al. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol. 2012; 22: 432-9.